| General Information |
| Business: |
(Incorporated in Delaware)
We are a clinical-stage biotech company focused on developing subcutaneous treatments for rare blood coagulation disorders. Our lead therapeutic candidate, sutacimig – also known as HMB-001, has completed Phase 2 trials and it’s ready for Phase 3 for the treatment of Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency. Our therapeutic candidate, HMB-002, is in Phase 1/2 trials for Von Willebrand Disease.
Note: Net loss is for the year that ended Dec. 31, 2025.
Note: The company has not generated any revenue.
(Note: Hemab Therapeutics Holdings, Inc. filed its S-1 on April 10, 2026, without disclosing the terms. Estimated proceeds are $100 million, a placeholder figure.)
|
| Industry: |
Pharmaceuticals |
| Employees: |
72 |
| Founded: |
2020 |
| Contact Information |
| Address |
|
| Phone Number |
|
| Web Address |
http://www.hemab.com/ |
| View Prospectus: |
Hemab Therapeutics Holdings, Inc. |
| Financial Information |
| Market Cap |
|
| Revenues |
$0.0 mil (last 12 months) |
| Net Income |
$-63.91 mil (last 12 months) |
| IPO Profile |
| Symbol |
COAG |
| Exchange |
NASDAQ |
| Shares (millions): |
0.0 |
| Price range |
$0.00 - $0.00 |
| Est. $ Volume |
$100.0 mil |
| Manager / Joint Managers |
Goldman Sachs/Jefferies/Evercore ISI |
| CO-Managers |
|
| Expected To Trade: |
|
|
Status:
|
TBA |
| Quiet Period Expiration Date: |
Available only to Subscribers |
| Lock-Up Period Expiration Date: |
Available only to Subscribers |
| SCOOP Rating |
Available only to Subscribers |
| Rating Change |
Available only to Subscribers |
